RiteMED Clindamycin

Lower resp tract infections including bronchitis, pneumonia, empyema, & lung abscess. URTIs including tonsillitis, pharyngitis, sinusitis, otitis media, & scarlet fever. Skin & skin structure infections including inflammatory acne vulgaris, furuncles, cellulitis, impetigo, abscesses, contaminated wounds, erysipelas & paronychia (panaritium). Gynecological infections including endometritis, pelvic cellulitis, post-surgical vag cuff infection, nongonococcal tubo-ovarian abscess, salpingitis & pelvic inflammatory disease in conjunction w/ antibiotic of appropriate gm -ve aerobic spectrum, cervicitis due to Chlamydia trachomatis as monotherapy. Intra-abdominal infections including peritonitis & abdominal abscess in conjunction w/ antibiotic of appropriate gm -ve aerobic spectrum. Bone & joint infections including acute hematogenous osteomyelitis & septic arthritis. Septicemia & endocarditis. Dental infections eg, periodontal abscess & periodontitis. Pneumocystis jiroveci (carinii) pneumonia in patients w/ AIDS & in combination w/ primaquine in patients w/ AIDS who are intolerant to or do not respond to conventional treatment. Prophylaxis of bacterial endocarditis in patients allergic to penicillin. Alternative treatment of multi-drug resistant Plasmodium falciparum infection in combination w/ quinine or amodiaquine.

Adult Serious infections 150-300 mg every 6 hr. More severe infections 300-450 mg every 6 hr. Acne 150 mg every 12 hr. Bacterial vaginosis 300 mg every 12 hr for 7 days. Cervicitis due to Chlamydia trachomatis 450 mg every 6 hr for 10-14 days. Pelvic inflammatory disease (inpatient treatment) Initially 900 mg IV clindamycin every 8 hr + IV antibiotic w/ appropriate gm -ve aerobic spectrum, then continue w/ oral clindamycin HCl 450 mg every 6 hr to complete 10-14 days of treatment. Prevention of bacterial endocarditis in penicillin-allergic patients 600 mg as single dose 30-60 min before procedure. Pneumocystis jiroveci (carinii) pneumonia in patients w/ AIDS 300-450 mg every 6-8 hr + primaquine for 21 days. Alternative treatment of multi-drug resistant Plasmodium falciparum infection 5-10 mg/kg bid + quinine or amodiaquine for at least 5 days.

May be taken with or without food: Take w/ full glass of water to avoid possibility of esophageal irritation.

Hypersensitivity to clindamycin or lincomycin.

Discontinue use if Clostridium difficile-associated diarrhea is suspected or confirmed; hypersensitivity or severe skin reaction occurs. Not to be used in patients w/ nonbacterial infections. Not to be used for meningitis. Atopic individuals as well as patients w/ history of GI disease particularly colitis. Prescribing in absence of a proven or strongly suspected bacterial infection or prophylactic indication may increase risk of antibiotic resistance. Overgrowth of non-susceptible organisms including fungi in long term or repeated use. Concomitant use w/ neuromuscular blocking agents. Perform blood exam routinely during therapy w/ primaquine to monitor potential hematologic toxicities. Perform periodic liver & kidney function tests & blood counts during prolonged therapy. Perform surgical drainage & removal of necrotic tissue in combination w/ antibiotic therapy. Severe renal &/or hepatic impairment accompanied by severe metabolic aberrations; monitor serum levels during high-dose therapy in these patients. Determine liver enzyme levels periodically in patients w/ severe liver disease. Pregnancy & lactation. Childn ≤16 yr. Monitor geriatric patients >60 yr for development of diarrhea.

CDAD & colitis/pseudomembranous colitis, nausea, vomiting, diarrhea, abdominal pain/cramps, tenesmus, flatulence, bloating, anorexia, wt loss, esophagitis, esophageal ulcers; generalized mild to moderate morbilliform-like (maculopapular) skin rashes, rash, urticaria, pruritus, fever, hypotension, anaphylaxis/anaphylactoid reactions; erythema multiforme, SJS, exfoliative & vesiculobullous dermatitis, vesiculobullous rashes, serious cutaneous adverse reaction, TEN, acute generalized exanthematous pustulosis, DRESS; jaundice, hepatic damage, transient increases in serum bilirubin, alkaline phosphatase, AST, rare cases of renal dysfunction as evidenced by azotemia, oliguria, &/or proteinuria, abnormalities in LFTs; vag infection/vaginitis; transient neutropenia (leukopenia), eosinophilia, thrombocytopenia, agranulocytosis, leukocytoclastic angiitis; polyarthritis; dysgeusia; lymphadenitis.

May enhance neuromuscular blocking actions w/ potential danger of resp depression of neuromuscular blocking agents eg, ether, tubocurarine & pancuronium. Antagonized bactericidal activity of aminoglycosides. Diminished activity of ampicillin against Staph aureus. Antagonism of bactericidal activity w/ erythromycin. Antagonized effect of anticholinesterases eg, neostigmine & physostigmine. May possibly reduce contraceptive effect of estrogen. Inactivated oral typhoid vaccine. Increased coagulation test results (prothrombin time/INR) &/or bleeding w/ vit K antagonists eg, warfarin, acenocoumarol & fluindione.

Other Antibiotics

J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.

Rx